Sign In
Buy TRML
$47.98
+0 (+0%)
At Close: Jan 27, 2026
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
01:03am, Tuesday, 09'th Sep 2025
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a lon
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targe
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
10:23am, Sunday, 31'st Aug 2025
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concor
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
10:55am, Friday, 15'th Aug 2025
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Wednesday, 13'th Aug 2025
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein wi
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
04:51pm, Tuesday, 20'th May 2025
Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing paci
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
04:05pm, Monday, 19'th May 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
07:30am, Friday, 02'nd May 2025
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tour
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
07:30am, Thursday, 13'th Mar 2025
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the s
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
07:15am, Monday, 03'rd Mar 2025
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
07:30am, Friday, 10'th Jan 2025
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
08:30am, Tuesday, 10'th Dec 2024
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
07:30am, Thursday, 14'th Nov 2024
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
07:30am, Thursday, 07'th Nov 2024
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry
Tourmaline Bio to Present at Upcoming Investor Conferences
07:30am, Thursday, 31'st Oct 2024
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
